SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 70.20 |
| Enterprise Value ($M) | 53.84 |
| Book Value ($M) | 9.37 |
| Book Value / Share | 1.46 |
| Price / Book | 7.50 |
| NCAV ($M) | 9.09 |
| NCAV / Share | 1.42 |
| Price / NCAV | 7.72 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3.65 |
| Return on Assets (ROA) | -0.88 |
| Return on Equity (ROE) | -0.97 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.06 |
| Current Ratio | 2.06 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 17.67 |
| Assets | 17.95 |
| Liabilities | 8.58 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Ikarian Capital, LLC | |||
| 13G/A | Alger Associates Inc | |||
| 13G/A | Tybourne Capital Management (hk) Ltd | |||
| 13G | Janus Henderson Group Plc | |||
| 13G/A | Biotechnology Value Fund L P | |||
| 13G/A | Perceptive Advisors Llc | |||
| 13G | Orbimed Advisors Llc | |||
| 13G | Boothbay Fund Management, Llc | |||
| 13G/A | Farallon Capital Partners, L.P. | |||
| 13G | Oliveira Steven Michael | |||
| 13D/A | Camac Fund, LP | 4.00 | -7.30 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| Powers of Attorney (contained in the signature page to this Annual Report on Form 10-K). | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 4,510 | 49,298 | 9.15 | |
| 2,561 | 10,788 | 23.74 | |
| 1,555 | 9,628 | 16.15 | |
| 2,828 | 19,499 | 14.50 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EVOK – Evoke Pharma, Inc. | EYEN – Eyenovia, Inc. |
| FBIO – Fortress Biotech, Inc. | FENC – Fennec Pharmaceuticals Inc. |
| FLGC – Flora Growth Corp. |
Financial data and stock pages provided by
Fintel.io